Abstract
The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.
Keywords: Metabolic syndrome, cardiometabolic syndrome, substrate metabolism, inflammation, obesity, insulin resistance, hypertension, dyslipidemia
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Molecular Determinants of the Cardiometabolic Phenotype
Volume: 10 Issue: 2
Author(s): Lisa de las Fuentes, Giovanni de Simone, Donna K. Arnett and Victor G. Davila-Roman
Affiliation:
Keywords: Metabolic syndrome, cardiometabolic syndrome, substrate metabolism, inflammation, obesity, insulin resistance, hypertension, dyslipidemia
Abstract: The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.
Export Options
About this article
Cite this article as:
de las Fuentes Lisa, de Simone Giovanni, K. Arnett Donna and G. Davila-Roman Victor, Molecular Determinants of the Cardiometabolic Phenotype, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/187153010791213119
DOI https://dx.doi.org/10.2174/187153010791213119 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Bradykinin Receptors in Ischemic Injury
Current Neurovascular Research Roles of Perilipins in Diseases and Cancers
Current Genomics Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry GRK2 Inhibition in Heart Failure: Something Old, Something New
Current Pharmaceutical Design Controversies About the Chromosomal Stability of Cultivated Mesenchymal Stem Cells: Their Clinical Use is it Safe?
Current Stem Cell Research & Therapy Stem Cell Therapy in Heart Diseases: A Review of Selected New Perspectives,Practical Considerations and Clinical Applications
Current Cardiology Reviews Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design New Targeted Therapies for Thyroid Cancer
Current Genomics Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Cardiovascular Disease in Patients with Diabetic Nephropathy
Current Molecular Medicine Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology Serelaxin: New Investigational Treatment in Acute Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Cellular Therapy for Myocardial Repair
Current Cardiology Reviews Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design